Editas Medicine CFO Parison Amy sold 453 shares at $3.04 per share on Sep. 3, 2026. Her remaining ownership stood at 13,839 shares after the transaction, giving investors a precise view of the executive’s holdings following the sale.
Key Highlights
- The transaction occurred on Sep. 3, 2026.
- Parison Amy serves as Editas Medicine’s senior vice president and chief financial officer.
- Her remaining Editas Medicine holdings totaled 13,839 shares.
Editas Medicine, Inc. (NASDAQ: EDIT) CFO Parison Amy sold 453 shares at $3.04 per share. The transaction took place on Sep. 3, 2026.
$3.04 Per-Share Sale Leaves 13,839 Shares
Parison Amy is Editas Medicine’s senior vice president and chief financial officer. The sale covered 453 shares of the company’s stock at a price of $3.04 per share. Following the transaction, Amy held 13,839 Editas Medicine shares. The post-transaction balance identifies the number of shares remaining under Amy’s ownership after the sale. The transaction price was stated on a per-share basis.
FAQs
Q: How many Editas Medicine shares did CFO Parison Amy sell?
A: According to the Form 4, Parison Amy sold 453 shares of Editas Medicine. The filing reported that the shares were sold at $3.04 per share on Sep. 3, 2026.
Q: What does the Editas Medicine CFO share sale mean for investors?
A: The filing reports that Parison Amy owned 13,839 Editas Medicine shares following the transaction. It also lists the reported sale price as $3.04 per share.
Q: When did the Editas Medicine CFO share transaction occur?
A: The transaction occurred on Sep. 3, 2026. Parison Amy was identified as Editas Medicine’s senior vice president and chief financial officer.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.